Successful High-Dosage Monotherapy of Tigecycline in a Multidrug-Resistant Klebsiella pneumoniae Pneumonia–Septicemia Model in Rats
Authors:
- Hessel Van der WeideHWHessel Van der Weide
- Marian T. Ten KateMKMarian T. Ten Kate
- Denise M. C. Vermeulen-De JonghDJDenise M. C. Vermeulen-De Jongh
- Aart Van der MeijdenAMAart Van der Meijden
- Rixt A. WijmaRWRixt A. Wijma
- Stefan A. BoersSBStefan A. Boers
- Mireille Van WestreenenMWMireille Van Westreenen
- John P. HaysJHJohn P. Hays
- Wil H. F. GoessensWGWil H. F. Goessens
- Irma A. J. M. Bakker-WoudenbergIBIrma A. J. M. Bakker-Woudenberg
Open Access
- 3 March 2020
- journal article
- research article
- Published by MDPI AG in Antibiotics
- Vol. 9 (3) , 109
Abstract
Background: Recent scientific reports on the use of high dose tigecycline monotherapy as a “drug of last resort” warrant further research into the use of this regimen for the treatment of severe multidrug-resistant, Gram-negative bacterial infections. In the current study, the therapeutic efficacy of tigecycline monotherapy was investigated and compared to meropenem monotherapy in a newly developed rat model of fatal lobar pneumonia–septicemia. Methods: A Klebsiella pneumoniae producing extended-spectrum β-lactamase (ESBL) and an isogenic variant producing K. pneumoniae carbapenemase (KPC) were used in the study. Both strains were tested for their in vitro antibiotic susceptibility and used to induce pneumonia–septicemia in rats, which was characterized using disease progression parameters. Therapy with tigecycline or meropenem was initiated at the moment that rats suffered from progressive infection and was administered 12-hourly over 10 days. The pharmacokinetics of meropenem were determined in infected rats. Results: In rats with ESBL pneumonia–septicemia, the minimum dosage of meropenem achieving survival of all rats was 25 mg/kg/day. However, in rats with KPC pneumonia–septicemia, this meropenem dosage was unsuccessful. In contrast, all rats with KPC pneumonia–septicemia were successfully cured by administration of high-dose tigecycline monotherapy of 25 mg/kg/day (i.e., the minimum tigecycline dosage achieving 100% survival of rats with ESBL pneumonia–septicemia in a previous study). Conclusions: The current study supports recent literature recommending high-dose tigecycline as a last resort regimen for the treatment of severe multidrug-resistant bacterial infections. The use of ESBL- and KPC-producing K. pneumoniae strains in the current rat model of pneumonia–septicemia enables further investigation, helping provide supporting data for follow-up clinical trials in patients suffering from severe multidrug-resistant bacterial respiratory infections.Keywords
Funding Information
- Seventh Framework Programme (604434 Pneumo-NP)
This publication has 56 references indexed in Scilit:
- High-Throughput Multilocus Sequence Typing: Bringing Molecular Typing to the Next LevelPLOS ONE, 2012
- Treatment Outcome of Bacteremia Due to KPC-Producing Klebsiella pneumoniae: Superiority of Combination Antimicrobial RegimensAntimicrobial Agents and Chemotherapy, 2012
- Bacteremic community-acquired pneumonia due to Klebsiella pneumoniae: Clinical and microbiological characteristics in Taiwan, 2001-2008BMC Infectious Diseases, 2010
- Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal ResearchPLOS Biology, 2010
- Hospital-Acquired Infections Due to Gram-Negative BacteriaNew England Journal of Medicine, 2010
- Development of a set of multiplex PCR assays for the detection of genes encoding important β-lactamases in EnterobacteriaceaeJournal of Antimicrobial Chemotherapy, 2010
- CTX-M Expression and Selection of Ertapenem Resistance in Klebsiella pneumoniae and Escherichia coliAntimicrobial Agents and Chemotherapy, 2009
- Effect of Porins and Plasmid-Mediated AmpC β-Lactamases on the Efficacy of β-Lactams in Rat Pneumonia Caused by Klebsiella pneumoniaeAntimicrobial Agents and Chemotherapy, 2006
- Extended-Spectrum β-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance ThreatClinical Microbiology Reviews, 2001
- Comparative Pharmacokinetics of the CarbapenemsClinical Pharmacokinetics, 2000